Russia Registers New Drug for Aggressive Breast Cancer
The Russian Ministry of Health registered the drug 'Areyma', based on camrelizumab, for a new indication — for the treatment of triple-negative breast cancer (TNBC).
Consensus
- Ministry of Health of Russia registered the drug 'Aremia' for the treatment of triple-negative breast cancer.
- The drug is based on camrelizumab and is used in combination with chemotherapy during the preoperative stage.
- The drug is produced by Petrovax Pharma in collaboration with the National Research Center for Epidemiology and Microbiology named after Gamaleya.
- The registration was granted for a new indication, expanding the drug's use beyond its original approvals.
- The drug is intended to improve pathological response rates and long-term prognosis for patients.
Points of divergence
- This is the first neoadjuvant immunotherapy option in Russia for highly aggressive breast cancer, which occurs more frequently in women under 50. — vesti
- The drug will significantly improve patient prognosis and reduce the risk of metastases. — vedomosti
- The implementation of this treatment method could save up to 4.7 billion rubles over five years. — vm
- The drug received registration approval in November 2024, initially for nasopharyngeal and esophageal cancer, and later for non-small cell lung cancer; it will be included in the list of essential medicines (ЖНВЛП) starting in 2026. — kommersant
Coverage (4 sources)
- In Russia, a drug for treating an aggressive subtype of breast cancer has been registered — Вести
- Ministry of Health approved new drug "Areyma" for treatment of breast cancer — Ведомости
- Drug for treatment of aggressive form of breast cancer registered in Russia — Вечерняя Москва
- Ministry of Health registered drug "Areyma" for treatment of breast cancer — Коммерсантъ